Video

Dr. Al-Sawaf on the Benefit of Fixed-Duration Obinutuzumab/Venetoclax in CLL

Othman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, physician, the University Hospital of Cologne, discusses the benefit of fixed-duration treatment with obinutuzumab (Gazyva) plus venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

In the phase 3 CLL14 trial (NCT02242942), investigators evaluated the efficacy and safety of fixed-duration obinutuzumab plus venetoclax vs obinutuzumab plus chlorambucil in patients with previously untreated CLL with preexisting conditions.

Five-year follow-up data showed that fixed-duration obinutuzumab plus venetoclax demonstrated a clear benefit, particularly regarding toxicity, Al-Sawaf says. Since adverse effects were observed only when patients were on treatment, the lack of prolonged toxicity gives fixed-duration treatment another advantage, Al-Sawaf concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP